Valneva SE (NAS:VALN)
$ 4.3307 0.1342 (3.2%) Market Cap: 351.65 Mil Enterprise Value: 398.38 Mil PE Ratio: 0 PB Ratio: 1.60 GF Score: 69/100

Valneva SE Analyst Call Transcript

Nov 13, 2023 / 02:00PM GMT
Release Date Price: $13.73 (-0.69%)
Operator

Good day, and thank you for standing by. Welcome to Valneva Announces U.S. FDA approval of World's First Chikungunya Vaccine, IXCHIQ. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Josh Drumm, VP, Global Investor Relations. Please go ahead.

Joshua Drumm
Valneva SE - VP of IR

Thank you, Nadia. Hello, and thank you for joining us. We're excited to discuss the recent FDA approval of IXCHIQ, the world's first chikungunya vaccine and the third vaccine the company has advanced from early development to commercialization. It's my pleasure to welcome you today. Please note that you can find our press release from Friday and the analyst presentation published earlier today available within the Investors section of our website.

I'm joined today by Valneva's CEO, Thomas Lingelbach; and Chief Medical Officer -- Chief Medical Officer, Juan Carlos Jaramillo, who will provide an overview of chikungunya and IXCHIQ, the market outlook and the ongoing planned

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot